Recent Research Analysts’ Ratings Changes for Sotera Health (SHC)

A number of research firms have changed their ratings and price targets for Sotera Health (NASDAQ: SHC):

• 6/24/2026 – Sotera Health was given a new $19.00 price target by UBS Group AG.
• 6/24/2026 – Sotera Health had its price target raised by Barclays PLC from $18.00 to $19.00. They now have an “overweight” rating on the stock.
• 6/5/2026 – Sotera Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $20.00 price target on the stock.
• 6/5/2026 – Sotera Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $20.00 price target on the stock.
• 5/21/2026 – Sotera Health was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 5/6/2026 – Sotera Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $22.00 price target on the stock, down from $24.00.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of Sotera Health stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total transaction of $193,194,516.17. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 15.36% of the company’s stock.

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.